search
Back to results

Safety and Efficacy of AIV001 on Low Risk Basal Cell Carcinoma

Primary Purpose

Superficial Basal Cell Carcinoma, Nodular Basal Cell Carcinoma

Status
Active
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
AIV001
Sponsored by
AiViva BioPharma, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Superficial Basal Cell Carcinoma focused on measuring Nonmelanoma Skin Cancer, Keratinocyte Carcinoma, NMSC, BCC

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Male or female, aged 18 to 80 years, inclusive
  2. No clinically relevant abnormalities identified by a detailed medical history and vital signs
  3. Presence of a histologically confirmed low risk BCC lesion, with well-defined borders, and with a largest diameter measure before biopsy of 5 mm to 20 mm, located on arms or trunk
  4. Histological diagnosis of the target lesion must have been conducted 5 to 30 days prior to Day 1
  5. No other dermatological disease within 50 mm of the target lesion at Day 1
  6. No prior or concurrent treatment of the target lesion (including radiation therapy)
  7. Willing to undergo surgical excision approximately 63 days after first treatment.

Exclusion Criteria:

  1. History or presence of systemic cancer
  2. Prior radiation treatment at the lesion site or anywhere else on the body within the past 20 years
  3. Concurrent disease or treatment that suppresses the immune system (eg, previous organ transplant history, etc.)
  4. Clinically relevant cardiovascular, endocrine, hepatic, neurologic, renal, or other major systemic disease that could complicate execution of the protocol or interpretation of the study results.
  5. History of thrombotic events, hemorrhagic events, and gastrointestinal perforation and fistula
  6. History of recurrence or presence of any other tumor subtype in the target lesion
  7. Concurrent presence of a malignant lesion within 100 mm of the target lesion that will require treatment during the study
  8. Current enrollment in any other investigational drug or device study within 60 days of Day 1 of this study
  9. Evidence of dermatological disease or confounding dermatological condition that would hinder carrying out the study or interpreting the results (eg, atopic dermatitis, eczema, psoriasis, xeroderma pigmentosa, etc.)

Sites / Locations

  • California Dermatology & Clinical Research Institute
  • Island Dermatology
  • Austin Institute for Clinical Research

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

Experimental

Arm Label

AIV001 Treatment Dose 1

AIV001 Treatment Dose 2

AIV001 Treatment Dose 3

AIV001 Treatment Dose 4

Arm Description

Intradermal/intratumoral, Dose 1

Intradermal/intratumoral, Dose 2

Intradermal/intratumoral, Dose 3

Intradermal/intratumoral, Dose 4

Outcomes

Primary Outcome Measures

Adverse events
Incidence of adverse events

Secondary Outcome Measures

Clearance of basal cell carcinoma
Number of participants cleared of basal cell carcinoma within study duration

Full Information

First Posted
July 10, 2020
Last Updated
April 11, 2023
Sponsor
AiViva BioPharma, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT04470726
Brief Title
Safety and Efficacy of AIV001 on Low Risk Basal Cell Carcinoma
Official Title
An Exploratory Study to Evaluate the Safety and Efficacy of AIV001 Intradermally Administered in Subjects With Biopsy-confirmed Basal Cell Carcinoma
Study Type
Interventional

2. Study Status

Record Verification Date
April 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
August 18, 2020 (Actual)
Primary Completion Date
June 23, 2023 (Anticipated)
Study Completion Date
June 23, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
AiViva BioPharma, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
To evaluate safety and efficacy of AIV001 treatment on low-risk basal cell carcinoma.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Superficial Basal Cell Carcinoma, Nodular Basal Cell Carcinoma
Keywords
Nonmelanoma Skin Cancer, Keratinocyte Carcinoma, NMSC, BCC

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Sequential Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
26 (Actual)

8. Arms, Groups, and Interventions

Arm Title
AIV001 Treatment Dose 1
Arm Type
Experimental
Arm Description
Intradermal/intratumoral, Dose 1
Arm Title
AIV001 Treatment Dose 2
Arm Type
Experimental
Arm Description
Intradermal/intratumoral, Dose 2
Arm Title
AIV001 Treatment Dose 3
Arm Type
Experimental
Arm Description
Intradermal/intratumoral, Dose 3
Arm Title
AIV001 Treatment Dose 4
Arm Type
Experimental
Arm Description
Intradermal/intratumoral, Dose 4
Intervention Type
Drug
Intervention Name(s)
AIV001
Intervention Description
Intradermal/intratumoral
Primary Outcome Measure Information:
Title
Adverse events
Description
Incidence of adverse events
Time Frame
Approximately 119 days
Secondary Outcome Measure Information:
Title
Clearance of basal cell carcinoma
Description
Number of participants cleared of basal cell carcinoma within study duration
Time Frame
Approximately 105 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female, aged 18 to 80 years, inclusive No clinically relevant abnormalities identified by a detailed medical history and vital signs Presence of a histologically confirmed low risk BCC lesion, with well-defined borders, and with a largest diameter measure before biopsy of 5 mm to 20 mm, located on arms or trunk Histological diagnosis of the target lesion must have been conducted 5 to 30 days prior to Day 1 No other dermatological disease within 50 mm of the target lesion at Day 1 No prior or concurrent treatment of the target lesion (including radiation therapy) Willing to undergo surgical excision approximately 63 days after first treatment. Exclusion Criteria: History or presence of systemic cancer Prior radiation treatment at the lesion site or anywhere else on the body within the past 20 years Concurrent disease or treatment that suppresses the immune system (eg, previous organ transplant history, etc.) Clinically relevant cardiovascular, endocrine, hepatic, neurologic, renal, or other major systemic disease that could complicate execution of the protocol or interpretation of the study results. History of thrombotic events, hemorrhagic events, and gastrointestinal perforation and fistula History of recurrence or presence of any other tumor subtype in the target lesion Concurrent presence of a malignant lesion within 100 mm of the target lesion that will require treatment during the study Current enrollment in any other investigational drug or device study within 60 days of Day 1 of this study Evidence of dermatological disease or confounding dermatological condition that would hinder carrying out the study or interpreting the results (eg, atopic dermatitis, eczema, psoriasis, xeroderma pigmentosa, etc.)
Facility Information:
Facility Name
California Dermatology & Clinical Research Institute
City
Encinitas
State/Province
California
ZIP/Postal Code
92024
Country
United States
Facility Name
Island Dermatology
City
Newport Beach
State/Province
California
ZIP/Postal Code
92660
Country
United States
Facility Name
Austin Institute for Clinical Research
City
Pflugerville
State/Province
Texas
ZIP/Postal Code
78660
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Safety and Efficacy of AIV001 on Low Risk Basal Cell Carcinoma

We'll reach out to this number within 24 hrs